BioSyent Announces Agreement to Purchase Tibelia® (tibolone) Assets

MISSISSAUGA, Ontario, Sept. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc., has entered into an agreement to acquire certain assets enabling it to supply Tibelia^®, a tibolone-based hormone replacement therapy drug, to distributors worldwide. Under an Asset Purchase Agreement entered into with the trustees of Novalon SA and Mithra Pharmaceuticals SA, BioSyent Pharma Inc. has acquired intellectual property, global rights, certain licensing, distribution and supply agreements related to Tibelia^® (tibolone), as well as certain inventory and equipment, for cash consideration of up to EUR 2.8 million, subject to certain post-closing conditions.  

Read more at globenewswire.com